A novel TB test developed by the EU project DEMO-NOPERSIST
Human tuberculosis (TB) is a global health problem of immense social and economic importance. There are more than 14 million individuals dually infected with TB and HIV. Diagnosis of human TB is extremely difficult, time-consuming and in-efficient. No efficient, cost effective tests are available for an early diagnosis of these infections. Furthermore, there is no test on the market which can differentiate billions of MTB-infected but otherwise healthy people (LTBI) from the patient suffering from active TB.
Research partners of the EU project DEMO-NOPERSIST, led by LIONEX GmbH as coordinator, have been successful in developing a novel test called LIOSpot® TB, which for the first time, can differentiate healthy infected from TB patients. LIOSpot® TB test is expected to have strong positive impact on human health and prevention of tuberculosis world-wide. LIONEX is now preparing the LIOSpot® TB test for marketing.
Following the successful completion of DEMO-NOPERSIST, LIONEX and University of Florence (UNIFI) shall continue their collaboration which led to the development of LIOSpot® TB.
LIONEX is a highly research intensive company dedicated to tuberculosis and has a prominent position in Europe in this field. LIONEX is ISO9001 and ISO13485 certified and has excellent infrastructure for large scale production of In-Vitro Diagnostic Device (IVD).
Prof. Dr. Mahavir Singh
Salzdahlumer Str. 196
Gebäude / Building 1A
Tel. +49(0)531 / 2601266
FAX +49(0)531 / 6180654
firstname.lastname@example.org / www.lionex.de
LIONEX is growing biotech company with exceptional commitment to the problems of tropical diseases such as TB and HIV infection. It is a partner of BioRegioN, a highly active biotech oriented region in Germany. LIONEX has excellent facilities and expertise in recombinant DNA technology, production of high quality recombinant proteins and monoclonal antibodies (mAbs) for research and diagnostics. In the last 15 years, more than 400 recombinant proteins of M. tuberculosis have already been produced by LIONEX and are available in significant quantities. Corresponding mAbs are available for a series of mycobacterial antigens. This fact shall be of considerable advantage for developing new diagnostic products (antigen and antibody detection) for TB. LIONEX has recently completed pre-clinical research on its novel Immunotherautic protein for the treatment of human superficial urinary bladder cancer (LIONEX-Patent). Prof. Singh, the CEO of LIONEX, has been engaged in research on mycobacterial antigens for the last 30 years. He has coordinated and / or supervised research projects funded by the WHO, European Commission, German Science Foundation and German Government. Prof. Singh is involved in national and international research projects on TB, HIV, Buruli ulcer, Malaria and mycobacterial genetics. He has coordinated several EU projects “NEW TB Drugs”, FASTEST-TB”, “NOPERSIST” and is currently coordinating DEMO-NOPERSIST (FP7 project).